The present study found a significant reduction in the levels of ERFE, ferroportin, leucocytes, platelets, and iron levels (ferritin, serum iron, sTFR, and transferrin) with significantly improved red cell indices (Hb, HCT, and RBC) in SCA participants on HU therapy compared to the HU-naïve participants. The gene discussed is SLC40A1; the disease is autosomal dominant cerebellar ataxia.